Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 5,201 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Neoplasm Clear all
Completed Not applicable Interventional

Innovative Approach to Reduce Lung Cancer Stigma

NCT03750864
View directory record Official record
Conditions
Lung Cancer Stigma, Lung Cancer, Stigma, Social, Stigmatization, Acceptance Processes
Interventions
ACT-LCS Therapy
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 28, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC

NCT02451930
View directory record Official record
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Necitumumab, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 28, 2026, 7:48 PM EDT
Terminated Early Phase 1 Interventional

Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer

NCT01261299
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Urinary Bladder Neoplasms
Interventions
Carbon-14-labeled carboplatin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 28, 2026, 7:48 PM EDT
Completed Early Phase 1 Interventional

UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.

NCT03224871
View directory record Official record
Conditions
METASTATIC NON-SMALL CELL LUNG CANCER
Interventions
Intralesional IL-2, Nivolumab, Pembrolizumab, Radiotherapy
Drug · Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 28, 2026, 7:48 PM EDT
Terminated Phase 1 Interventional

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

NCT05153408
View directory record Official record
Conditions
Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR C797S, EGFR C797A, EGFR L858R, EGFR Exon 19 Deletion, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Thoracic Neoplasms, Antineoplastic Agents, Protein Kinase Inhibitors, EGFR C797G, EGFR C797X, Non Small Cell Lung Cancer
Interventions
BLU-701, osimertinib, carboplatin, pemetrexed
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 28, 2026, 7:48 PM EDT
Withdrawn Phase 2 Interventional

Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)

NCT01336543
View directory record Official record
Conditions
Stage III Non-small Cell Lung Cancer
Interventions
Chemotherapy following concurrent Chemoradiotherapy
Drug
Lead sponsor
Syed Jafri
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 28, 2026, 7:48 PM EDT
Terminated Not applicable Interventional Results available

Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine

NCT01654068
View directory record Official record
Conditions
Vertebral Metastasis
Interventions
Conformal High Dose Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Ronald McGarry
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 28, 2026, 7:48 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

NCT05669430
View directory record Official record
Conditions
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
Biological
Lead sponsor
GV20 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 28, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

PT-112 in Subjects With Thymoma and Thymic Carcinoma

NCT05104736
View directory record Official record
Conditions
Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
Interventions
PT-112
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 7:48 PM EDT
Recruiting Phase 1 Interventional

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

NCT07020117
View directory record Official record
Conditions
Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer
Interventions
[225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
Drug
Lead sponsor
Aktis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
14
States / cities
Duarte, California • Irvine, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 28, 2026, 7:48 PM EDT
Recruiting No phase listed Observational

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

NCT07028489
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
N-Power Medicine
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Monterey, California • Torrance, California • Walnut Creek, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 28, 2026, 7:48 PM EDT
Terminated Phase 1 Interventional Results available

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

NCT00424840
View directory record Official record
Conditions
Lung Cancer
Interventions
Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Bortezomib 1.8 mg/m2, Carboplatin AUC 6, Bevacizumab, Taxotere
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 28, 2026, 7:48 PM EDT
Active, not recruiting Phase 2 Interventional

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

NCT04268550
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Selpercatinib
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
306
States / cities
Fairbanks, Alaska • Little Rock, Arkansas • Anaheim, California + 251 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 28, 2026, 7:48 PM EDT
Completed Phase 2 Interventional

Amifostine, Chemotherapy, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00004176
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions
amifostine trihydrate, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
4
States / cities
Denver, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 28, 2026, 7:48 PM EDT
Active, not recruiting Phase 1 Interventional

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

NCT04526691
View directory record Official record
Conditions
Advanced or Metastatic NSCLC
Interventions
Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 28, 2026, 7:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

NCT06024174
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986466, Adagrasib, Cetuximab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Athens, Georgia • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 28, 2026, 7:48 PM EDT
Completed Not applicable Interventional

Combined Deep Inspiration Breath Hold (DIBH)-Expiration Planning Technique in Patients With Lung Tumors in Close Proximity to the Chest Wall

NCT04507828
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
Treatment Planning using the DIBH Technique
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 28, 2026, 7:48 PM EDT
Recruiting No phase listed Observational

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT06904365
View directory record Official record
Conditions
Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer
Interventions
HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 7:48 PM EDT
Completed Phase 2 Interventional Results available

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

NCT01222767
View directory record Official record
Conditions
Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET), Askin's Tumor of the Chest Wall, Extraosseous Ewing's Sarcoma (EOE)
Interventions
Zalypsis
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
16 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Santa Monica, California • Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 28, 2026, 7:48 PM EDT
Completed Phase 2 Interventional

Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer

NCT00039507
View directory record Official record
Conditions
Lung Cancer
Interventions
conventional surgery, radiofrequency ablation
Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2010 · Synced Oct 28, 2026, 7:48 PM EDT
Completed Not applicable Interventional

Feasibility Study of Anatomical Modeling for Image Guided Thoracic Surgery

NCT05046067
View directory record Official record
Conditions
Lung Neoplasm
Interventions
Computed Tomography, Therapeutic Conventional Surgery
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 28, 2026, 7:48 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Taletrectinib
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
20
States / cities
Beverly Hills, California • Glendale, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 28, 2026, 7:48 PM EDT
Available No phase listed Expanded access

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

NCT04146571
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, ALK Gene Rearrangement Positive
Interventions
Ensartinib
Drug
Lead sponsor
Xcovery Holdings, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
4
States / cities
Stanford, California • Bethesda, Maryland • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 28, 2026, 7:48 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)

NCT04200534
View directory record Official record
Conditions
Smoking, Lung Cancer
Interventions
Best Practice, Nicotine Patch, Quality-of-Life Assessment, Questionnaire Administration, Tobacco Cessation Counseling
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
55 Years to 77 Years
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
3
States / cities
Galveston, Texas • Houston, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 28, 2026, 7:48 PM EDT